SCHEMBL3107465

SCHEMBL3107465

CCCc1c(C(=O)NC2CC2)nnn1-c1ccc(NC(=O)CC)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ROCK1 Q13464 1/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ HTT P42858 1/20 0.44
▸ SMYD3 Q9H7B4 1/20 0.41
▸ POLB P06746 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ RXFP1 Q9HBX9 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.38
▸ MAPT P10636 2/20 0.38
▸ RIPK2 O43353 1/20 0.38
▸ GAA P10253 2/20 0.38
▸ RIPK1 Q13546 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ NPC1 O15118 3/20 0.37
▸ RAB9A P51151 3/20 0.37
▸ TP53 P04637 1/20 0.37
▸ F10 P00742 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3111198 0.93 ROCK1 (0.49) ROCK1SMN1; SMN2SMYD3POLBMEN1
SCHEMBL3117945 0.92 ROCK1 (0.48) ROCK1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL3108746 0.92 ROCK1 (0.46) ROCK1SMN1; SMN2SMYD3POLBRXFP1
SCHEMBL3115899 0.91 ROCK1 (0.47) ROCK1POLBMEN1KMT2ARXFP1
SCHEMBL3099742 0.91 ROCK1 (0.48) ROCK1SMN1; SMN2SMYD3POLBMEN1
SCHEMBL3107068 0.90 ROCK1 (0.47) ROCK1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL3100915 0.90 ROCK1 (0.45) ROCK1POLBRXFP1ALDH1A1MAPT
SCHEMBL3106667 0.90 ROCK1 (0.45) ROCK1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL3113422 0.90 ROCK1 (0.47) ROCK1POLBMEN1KMT2ARXFP1
SCHEMBL3105282 0.90 ROCK1 (0.47) ROCK1SMN1; SMN2HTTPOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 — — US disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 — — US disclosed
EP-1867331-A1 TRIAZOLE DERIVATIVE AND THE USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-12-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105253-A1 Triazole Derivative and Use Thereof F2R, HRH4, F2RL3 ROCK1 1430/4885SMN1; SMN2 4399/4885HTT 969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback